0001209191-20-044098.txt : 20200730 0001209191-20-044098.hdr.sgml : 20200730 20200730194852 ACCESSION NUMBER: 0001209191-20-044098 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200730 DATE AS OF CHANGE: 20200730 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rosenberg Noah L. CENTRAL INDEX KEY: 0001579649 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 201062408 MAIL ADDRESS: STREET 1: C/O ESPERION THERAPEUTICS, INC. STREET 2: 46701 COMMERCE CENTER DRIVE CITY: PLYMOUTH STATE: MI ZIP: 48170 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Retrophin, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3721 VALLEY CENTRE DR. STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 760-260-8600 MAIL ADDRESS: STREET 1: 3721 VALLEY CENTRE DR. STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 0 0001438533 Retrophin, Inc. RTRX 0001579649 Rosenberg Noah L. C/O RETROPHIN, INC. 3721 VALLEY CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92130 0 1 0 0 Chief Medical Officer Common Stock 2020-07-28 4 S 0 870 20.49 D 26055 D Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Includes 197 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program. /s/ Elizabeth E. Reed, Attorney-in-Fact 2020-07-30